LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2270

Search options

  1. Article ; Online: Sheep, Meet Stupp.

    Lo, Simon S / Chang, Eric L

    International journal of radiation oncology, biology, physics

    2021  Volume 109, Issue 5, Page(s) 1139–1140

    MeSH term(s) Animals ; Dacarbazine ; Sheep ; Temozolomide
    Chemical Substances Dacarbazine (7GR28W0FJI) ; Temozolomide (YF1K15M17Y)
    Language English
    Publishing date 2021-03-05
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2020.01.038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.

    Chang, Hewitt / Marquez, Jaqueline / Chen, Brandon K / Kim, Daniel M / Cheng, Michael L / Liu, Eric V / Yang, Hai / Zhang, Li / Sinha, Meenal / Cheung, Alexander / Kwek, Serena S / Chow, Eric D / Bridge, Mark / Aggarwal, Rahul R / Friedlander, Terence W / Small, Eric J / Anderson, Mark / Fong, Lawrence

    Cancer immunology research

    2024  Volume 12, Issue 4, Page(s) 453–461

    Abstract: Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK-RANKL interactions regulate bone turnover by controlling ... ...

    Abstract Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK-RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints. See related Spotlight by Nasrollahi and Davar, p. 383.
    MeSH term(s) Humans ; Male ; Bone Neoplasms/drug therapy ; Bone Neoplasms/prevention & control ; Bone Neoplasms/secondary ; Denosumab/therapeutic use ; Kidney Neoplasms/drug therapy ; RANK Ligand/antagonists & inhibitors ; Prostatic Neoplasms/drug therapy
    Chemical Substances Denosumab (4EQZ6YO2HI) ; RANK Ligand
    Language English
    Publishing date 2024-01-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-23-0184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Preserving Neurocognition in Patients With Brain Metastases.

    Chang, Eric L

    JAMA oncology

    2016  Volume 3, Issue 2, Page(s) 269–270

    Language English
    Publishing date 2016-09-22
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2016.3944
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: spaB

    Chang, Ri K / Pomaranski, Eric K / Giray, Cem / Keleher, William / Griffin, Matt J / Camus, Alvin C / Toohey-Kurth, Kathy L / Soto, Esteban

    Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc

    2023  , Page(s) 10406387231209035

    Abstract: Members of the ... ...

    Abstract Members of the genus
    Language English
    Publishing date 2023-11-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 287603-6
    ISSN 1943-4936 ; 1040-6387
    ISSN (online) 1943-4936
    ISSN 1040-6387
    DOI 10.1177/10406387231209035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Binding Affinity, Selectivity, and Pharmacokinetics of the Oxytocin Receptor Antagonist L-368,899 in the Coyote (

    Freeman, Sara M / Catrow, J Leon / Cox, James Eric / Turano, Alexandra / Rich, McKenna A / Ihrig, Hillary P / Poudyal, Naveena / Chang, Cheng-Wei Tom / Gese, Eric M / Young, Julie K / Olsen, Aaron L

    Comparative medicine

    2024  Volume 74, Issue 1, Page(s) 3–11

    Abstract: L-368,899 is a selective small-molecule oxytocin receptor (OXTR) antagonist originally developed ... in the 1990s to prevent preterm labor. Although its utility for that purpose was limited, L-368,899 is now one ... delivery. A growing number of rodent and primate studies have used L-368,899 to evaluate whether certain ...

    Abstract L-368,899 is a selective small-molecule oxytocin receptor (OXTR) antagonist originally developed in the 1990s to prevent preterm labor. Although its utility for that purpose was limited, L-368,899 is now one of the most commonly used drugs in animal research for the selective blockade of neural OXTR after peripheral delivery. A growing number of rodent and primate studies have used L-368,899 to evaluate whether certain behaviors are oxytocin dependent. These studies have improved our understanding of oxytocin's function in the brains of rodents and monkeys, but very little work has been done in other mammals, and only a single paper in macaques has provided any evidence that L-368,899 can be detected in the CNS after peripheral delivery. The current study sought to extend those findings in a novel species: coyotes (
    MeSH term(s) Animals ; Receptors, Oxytocin ; Coyotes/physiology ; Oxytocin ; Primates ; Vasopressins ; Camphanes ; Piperazines
    Chemical Substances Receptors, Oxytocin ; L 368899 (ER33G946JT) ; Oxytocin (50-56-6) ; Vasopressins (11000-17-2) ; Camphanes ; Piperazines
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2006425-1
    ISSN 2769-819X ; 0023-6764 ; 1532-0820
    ISSN (online) 2769-819X
    ISSN 0023-6764 ; 1532-0820
    DOI 10.30802/AALAS-CM-23-000044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Urethral Bulking With Polyacrylamide Hydrogel Compared With Other Treatments for Stress Urinary Incontinence: A Cost-Effectiveness Analysis.

    Chang, Olivia H / Shepherd, Jonathan P / Cadish, Lauren A / Wallace, Shannon L / St Martin, Brad / Sokol, Eric R

    Obstetrics and gynecology

    2024  Volume 143, Issue 3, Page(s) 428–430

    Abstract: Our objective was to perform a cost-effectiveness analysis comparing polyacrylamide hydrogel urethral bulking with other surgical and nonsurgical treatments for stress urinary incontinence (SUI). We created a cost-effectiveness analysis using TreeAge Pro, ...

    Abstract Our objective was to perform a cost-effectiveness analysis comparing polyacrylamide hydrogel urethral bulking with other surgical and nonsurgical treatments for stress urinary incontinence (SUI). We created a cost-effectiveness analysis using TreeAge Pro, modeling eight SUI treatments. Treatment with midurethral sling (MUS) had the highest effectiveness (1.86 quality-adjusted life-years [QALYs]), followed by polyacrylamide hydrogel (1.82 QALYs), with a difference (Δ 0.02/year) less than the minimally important difference for utilities of 0.03 annually. When the proportion of polyacrylamide hydrogel urethral bulking procedures performed in the office setting is greater than 58%, polyacrylamide hydrogel is a cost-effective treatment for SUI, along with pessary, pelvic floor physical therapy, and MUS. Although MUS is more effective and, therefore, the preferred SUI treatment, polyacrylamide hydrogel is a reasonable alternative depending on patient preferences and treatment goals.
    MeSH term(s) Humans ; Urinary Incontinence, Stress/surgery ; Cost-Effectiveness Analysis ; Acrylic Resins ; Urethra ; Treatment Outcome ; Suburethral Slings
    Chemical Substances polyacrylamide gels ; Acrylic Resins
    Language English
    Publishing date 2024-01-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000005503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Preserve the Facial Nerve.

    Lo, Simon S / Chang, Eric L

    International journal of radiation oncology, biology, physics

    2019  Volume 103, Issue 4, Page(s) 798–799

    MeSH term(s) Cranial Nerve Neoplasms ; Facial Nerve ; Headache ; Hearing Loss ; Humans
    Language English
    Publishing date 2019-03-07
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2018.11.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer.

    Leow, Jeffrey J / Ray, Shagnik / Dason, Shawn / Singer, Eric A / Chang, Steven L

    The Urologic clinics of North America

    2023  Volume 50, Issue 2, Page(s) 285–303

    Abstract: Because metachronous metastatic disease will develop in 20% to 40% of patients with presumed localized renal cell carcinoma (RCC) treated surgically, research is focused on neoadjuvant and adjuvant systemic therapy, to improve disease-free and overall ... ...

    Abstract Because metachronous metastatic disease will develop in 20% to 40% of patients with presumed localized renal cell carcinoma (RCC) treated surgically, research is focused on neoadjuvant and adjuvant systemic therapy, to improve disease-free and overall survival. Neoadjuvant therapies trialed include anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) agents, or combination therapies (immunotherapy with TKI), and aim to improve resectability of locoregional RCC. Adjuvant therapies trialed include cytokines, anti-VEGF TKI agents, or immunotherapy. These therapeutics can facilitate the surgical extirpation of the primary kidney tumor in the neoadjuvant setting and improve disease-free survival in the adjuvant setting.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/pathology ; Neoadjuvant Therapy ; Kidney Neoplasms/pathology ; Combined Modality Therapy ; Disease-Free Survival ; Adjuvants, Immunologic
    Chemical Substances Adjuvants, Immunologic
    Language English
    Publishing date 2023-02-20
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 192293-2
    ISSN 1558-318X ; 0094-0143
    ISSN (online) 1558-318X
    ISSN 0094-0143
    DOI 10.1016/j.ucl.2023.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Effect Size and Blinding in Lumateperone Trial.

    Gouse, Brittany M / Chang, Alexander L / Smith, Eric G

    JAMA psychiatry

    2020  Volume 77, Issue 6, Page(s) 650–651

    MeSH term(s) Antipsychotic Agents/therapeutic use ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Heterocyclic Compounds, 4 or More Rings ; lumateperone (70BSQ12069)
    Language English
    Publishing date 2020-04-21
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2020.0610
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: In Regard to Dr Vapiwala.

    Jennelle, Richard / Chang, Eric L

    International journal of radiation oncology, biology, physics

    2017  Volume 98, Issue 1, Page(s) 215

    Language English
    Publishing date 2017-05-01
    Publishing country United States
    Document type Letter
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2017.01.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top